Konica Minolta Healthcare and RegenLab expand ultrasound solutions

20 February 2020 (Last Updated February 20th, 2020 12:31)

Konica Minolta Healthcare Americas has entered a partnership with RegenLab USA for the distribution of its regenerative medicine portfolio of bio-injectable products in the US and Canada.

Konica Minolta Healthcare and RegenLab expand ultrasound solutions
Konica Minolta Healthcare and RegenLab USA partnership is aimed to distribute its regenerative medicine portfolio of bio-injectable products in US and Canada. Credit: Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare Americas has entered a partnership with RegenLab USA for the distribution of its regenerative medicine portfolio of bio-injectable products in the US and Canada.

The portfolio of bio-injectable products caters to the musculoskeletal (MSK), pain management, radiology and veterinary markets.

This bio-injectable line features preparation devices for Platelet Rich Plasma (PRP) and other blood cell therapies delivered using ultrasound guidance.

The partnership with RegenLab is also expected to broaden Konica Minolta’s UGPro Solution, a programme that helps to improve patient outcomes by combining ultrasound imaging with targeted therapies and hands-on education.

Through this partnership, Konica Minolta intends to tap the growing demand for PRP, a concentration of platelets in plasma from a patient’s own blood (autologous).

Konica Minolta ultrasound sales executive vice-president Eric Sumner said: “Our partnership with RegenLab gives our customers a complete solution, from the highest quality ultrasound systems to excellent PRP and cell therapy products, so they can maximise the quality of care for their patients and get them back to being active again.

“We are excited to add RegenLab’s biologic therapies to our comprehensive UGPro Solution.”

RegenLab’s PRP preparations kits allow rapid and consistent preparation from a small volume of blood with an optimal platelet concentration and viability.

The procedures are performed under ultrasound guidance to enable the practitioner to visualise the needle in real-time and precisely target the desired spot.

Due to ultrasound guidance, the accuracy of nearly every joint injection is claimed to exceed 90%.